Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 28  •  03:40PM ET
18.07
Dollar change
+0.49
Percentage change
2.78
%
CategoryTarget Date / Multi-Asset - Other Asset TypeMulti-Asset - Tactical / Active TagsU.S. Return% 1Y-13.62% Total Holdings31 Perf Week9.23%
SponsorSimplify ETF ETF Type Tagsequity Return% 3Y- AUM81.04M Perf Month5.91%
Fund Family Bond Type Tagsbonds Return% 5Y- NAV/sh Perf Quarter10.82%
Index- Average Maturity Tagsmulti-asset Return% 10Y 52W High23.34 -22.58% Perf Half Y24.82%
Index Weighting Commodity Type Tagshealthcare Return% SI 52W Low12.71 42.22% Perf YTD17.60%
Active/Passive Quant Type Tagsbiotechnology Flows% 1M0.00% Volatility1.63% 1.92% Perf Year-20.66%
Dividend TTM2.72 (15.05%) ESG Type Tagspharmaceutical Flows% 3M1.60% ATR (14)0.38 Perf 3Y-
Dividend Ex-DateSep 25, 2025 Dividend Type Sector/Theme Flows% YTD-0.08% RSI (14)68.52 Perf 5Y-
Dividend Gr. 3/5Y- - Structure Type Region Flows% 1Y Beta1.18 Perf 10Y-
Expense2.57% Growth/Value SMA209.01% Flows% 3Y Rel Volume0.86 Prev Close17.58
Inverse/Leveraged Market Cap SMA509.40% Flows% 5Y Avg Volume3.91K Price18.07
IPOFeb 10, 2023 Option/ShortNo / Yes SMA20014.91% Trades Volume3,352 Change2.78%
Simplify Propel Opportunities ETF seeks to provide long-term growth of capital. The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.